<DOC>
	<DOCNO>NCT02959762</DOCNO>
	<brief_summary>Animal study find vitamin K-dependent protein matrix Gla protein osteocalcin beneficially influence lipid glucose metabolism , respectively . However , concept test human risk dyslipidemia diabetes risk . Vitamin K supplementation present opportunity test hypothesize link vitamin K-dependent protein marker lipid glucose metabolism . The investigator conduct 8-week vitamin K intervention ( manipulate carboxylation matrix Gla protein osteocalcin ) determine effect marker dyslipidemia diabetes risk . Sixty obese child randomly allocate either control group receive placebo low-dose ( 45 mcg/d ) high-dose group ( 90 mcg/d ) receive vitamin K ( menaquinone-7 ) .</brief_summary>
	<brief_title>Vitamin K Slow Progression Dyslipidemia Diabetes Risk ( Vita-K ' n ' Kids Study II )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<criteria>Age 8 17 year Body mass index equal great 95th percentile age sex Presence prediabetes , define American Diabetes Association Guidelines ( fast blood glucose 100125 mg/dl and/or A1C blood test measure 5.76.4 % ) Subject parent/guardian understands study protocol agrees comply Informed Consent Form sign parent/guardian assent sign subject Subjects use vitamin supplement contain vitamin k Subjects ( history ) metabolic gastrointestinal disease include hepatic disorder Subjects present chronic degenerative and/or inflammatory diseases Subjects receive systemic treatment topical treatment likely interfere evaluation study parameter ( salicylate , antibiotic ) Subjects receive corticosteroid treatment Subjects use oral anticoagulant Subjects history soy allergy Subjects participate clinical study recently one month current study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>G01 [ Biological Sciences ]</keyword>
	<keyword>G02.513 [ Nutrition ]</keyword>
	<keyword>G06.696.259 [ Child Nutrition ]</keyword>
	<keyword>G07.553.481.398.571 [ Obesity ]</keyword>
	<keyword>G06 [ Biochemical Phenomena , Metabolism , Nutrition ]</keyword>
	<keyword>G12.392.617 [ Insulin Resistance ]</keyword>
	<keyword>G06.696.259.500 [ Adolescent Nutrition ]</keyword>
	<keyword>A06 [ Endocrine System ]</keyword>
	<keyword>A07 [ Cardiovascular System ]</keyword>
	<keyword>C18.452.297.681 [ Obesity Diabetes ]</keyword>
	<keyword>C18.452.555 [ Insulin Resistance ]</keyword>
	<keyword>C18 [ Nutritional Metabolic Diseases ]</keyword>
	<keyword>C18.452.494 [ Hyperlipidemia ]</keyword>
	<keyword>C18.452.460 [ Hyperglycemia ]</keyword>
	<keyword>C14 [ Cardiovascular Diseases ]</keyword>
	<keyword>D11.786.875.844 [ Vitamin K 2 ]</keyword>
	<keyword>D02.806.550.750 [ Vitamin K 2 ]</keyword>
	<keyword>E02.293 [ Diet Therapy ]</keyword>
	<keyword>E02 [ Therapeutics ]</keyword>
	<keyword>F04.096.544.215.508.428 [ Primary Prevention ]</keyword>
	<keyword>N01.224.425.525 [ Nutritional Status ]</keyword>
</DOC>